3062 results about "Receptor" patented technology

The invention discloses a ligand information generation model training method and device and a ligand information generation method and device, and belongs to the technical field of artificial intelligence. The method comprises the following steps: acquiring sample receptor information and sample ligand information, wherein the binding affinity between a ligand described by the sample ligand information and a receptor described by the sample receptor information is not less than a set affinity; denoising the reference noise data based on the sample receptor information through a to-be-trained neural network model to obtain predicted ligand information; determining a first loss for characterizing a difference between the sample ligand information and the predicted ligand information; and training the neural network model based on the first loss to obtain a ligand information generation model. The reference ligand information can be generated based on the reference receptor information through the ligand information generation model, and the binding affinity between the ligand described by the reference ligand information and the receptor described by the reference receptor information is high.

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

The invention relates to antarctic krill peptide with umami and an antarctic krill peptide mixture as well as a preparation method and application thereof. Specifically, the amino acid sequence of the euphausia superba peptide is shown as any one of SEQ ID NO: 1-5. The euphausia superba peptide mixture with delicate flavor is obtained by carrying out enzyme digestion treatment on an euphausia superba peptide solution by using incision enzyme, excision enzyme and freshness enhancing enzyme and harvesting supernate. Molecular docking simulation shows that the euphausia superba peptide disclosed by the invention can be combined with a delicate flavor receptor T1R1 / T1R3. The Antarctic krill peptide and the Antarctic krill peptide mixture can be used for development of umami seasonings, and a new idea is provided for development of marine seasonings.

The present disclosure provides in some embodiments, a multi -objective binder design framework by aligning autoregressive molecular foundation models (e.g., protein language models (pLMs)) to different objectives, such as binding and developability considerations. In some embodiments, direct preference optimization (DPO) can be utilized in the methods and systems described herein to encode multiple design objectives in the language model through direct optimization on expert curated preference sequence datasets comprising preferred and dispreferred distributions. In some embodiments, utilizing the described framework can enable molecular foundation models (e.g., protein language models), such as ProtGPT2, to effectively design binders conditioned on specified receptors and one or more drug developability criteria. Besides being multi -objective, in some embodiments, the methods and systems provided herein conceive online lab-in-the-loop design pipelines by actively incorporating experimental feedback.

The invention discloses a tumor cholesterol metabolism regulation microneedle patch and a preparation method, the microneedle patch comprises a needle tip and a backing which are connected, the needle tip comprises a needle tip body and nanoparticles loaded on the needle tip body, the nanoparticle is a manganese ion-doped organic metal framework, the outer layer of the manganese ion-doped organic metal framework is modified with a targeting agent, cholesterol oxidase and superoxide dismutase are carried on the manganese ion-doped organic metal framework, the targeting agent can target a CD44 receptor, and the organic metal framework can carry drugs. The targeted drug can enter tumor cells in a targeted mode, superoxide dismutase catalyzes superoxide anions overexpressed in the tumor cells to generate H2O2 and O2, O2 needed by catalysis is provided for cholesterol oxidase, cholesterol at the tumor site is consumed by the cholesterol oxidase, accumulation of 7-DHC is reduced, meanwhile H2O2 can be generated, and the cholesterol oxidase can be used for catalyzing the tumor site. H2O2 is catalyzed by manganese ions through a Fenton-like reaction to generate OH to induce tumor cells to generate ferroptosis, so that ferroptosis-immune synergistic treatment is realized.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The invention discloses a bacteriophage host prediction method based on a weighted integrated convolutional neural network. The method comprises the following steps: obtaining a joint feature vector for an input bacteriophage protein sequence and a host receptor protein sequence; taking the bacteriophage-host pair as a positive sample, randomly selecting non-host bacteria for each bacteriophage to generate a negative sample, dividing the negative sample into M subsets, and combining each subset with all the positive samples to form M balance training subsets; for each balance training subset, training an independent one-dimensional convolutional neural network model; independently training a one-dimensional convolutional neural network sub-model for each balance training subset to obtain a plurality of sub-models with different performances; and distributing weights based on the performance indexes of the sub-models on the verification set, performing weighted fusion on the prediction probabilities of the M sub-models, and outputting a final host interaction probability. The method realizes accurate prediction of phage-host interaction on the premise of only needing basic sequence information, and has the advantages of light weight, high efficiency and wide applicability.

The invention discloses a receptor-like protein kinase gene containing a Malectin-like structural domain and associated with the heat resistance character of cotton, and belongs to the field of biotechnology application. The invention provides a cDNA (complementary deoxyribonucleic acid) sequence (SEQ ID NO.1) and a genomic sequence (SEQ ID NO.2) of the gene in allotetraploid upland cotton, 456 upland cotton varieties can be divided into two haplotype promoters according to a heat-resistant character GWAS associated site A11: 20036111, the sequence of a CC heat-labile haplotype promoter is shown as SEQ ID NO.3, and the sequence of a TT heat-resistant haplotype promoter is shown as SEQ ID NO.4. The invention also provides a method for preparing the promoter. The gene provided by the invention is obtained by cotton variety re-sequencing and whole genome association analysis, and is significantly associated with the heat-resistant character of cotton, and two promoter haplotypes of the gene are utilized to distinguish heat-resistant and non-heat-resistant haplotypes. The gene has important research value and application prospect in improvement of the heat-resistant character of cotton and cultivation of new heat-resistant varieties of cotton.

The invention belongs to the technical field of protein, and relates to a peptide for promoting synthesis of a brain-derived neurotrophic factor (BDNF) as well as a preparation method and application of the peptide. The amino acid sequence of the peptide for promoting synthesis of the brain-derived neurotrophic factor BDNF is SGFSKHF, and the peptide has the main effects that damage of CORT (corticosterone) to PC12 cells can be protected, the peptide can be spontaneously combined with a TrkB receptor, the structure of a compound formed after combination is more stable, BDNF-TrkB-CREB pathway signal transduction can be activated, generation of the BDNF is promoted, and the effect of promoting synthesis of the brain-derived neurotrophic factor BDNF is achieved. Therefore, the occurrence and development of neurodegenerative diseases can be delayed.

The invention discloses a deep learning-based umami peptide prediction method and system. The method comprises the following steps of S1, constructing a data set; s2, feature selection and processing; s3, constructing a Umami-Transform model: constructing the Umami-Transform model which comprises a feature processing and generating module, a sequence information processing module, a feature information processing module and a result output module; s4, model training; and S5, umami peptide prediction: inputting a peptide sequence to be detected into the trained Umami-Transformer model to obtain a probability prediction result that the peptide sequence is the umami peptide. According to the method, the Transform architecture and eight key physical and chemical characteristics are fused, so that peptide sequence information can be efficiently processed, and the prediction precision of the umami peptide is remarkably improved. All dipeptides to pentapeptides are screened by further combining with an exhaustion method, and an interaction mechanism between candidate peptides and the umami receptor T1R1 / T1R3 is analyzed through a molecular docking technology, so that the whole-process research from theoretical prediction to biological experimental verification is finally realized, and an innovative technical path is provided for efficient excavation and functional application of the umami peptides.

The invention relates to the field of tumor cell therapy, in particular to application of T lymphocyte chimeric with a B7-H3 receptor to treatment of head and neck tumors, and provides an anti-B7-H3 scFv, the scFv comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises an HCDR region and an HFR region, and the light chain variable region comprises an LCDR region and an LFR region; compared with a wild type scFv sequence, the scFv sequence has the advantage that a plurality of amino acids with positive charges in the HFR region and / or the LFR region are mutated into amino acids without charges. According to the invention, positive charge plaques on the CAR surface of an scFv sequence of a B7-H3 human-derived monoclonal antibody MGA271 are changed in a charged amino acid mutation manner, so that a B7-H3. CAR-T cell is optimized, and it is proved that the B7-H3. CAR-T cell optimized by PCP can effectively kill B7-H3 positive tumor cells in vivo and in vitro; and a new method and thought are provided for clinical targeted treatment of B7-H3 positive solid tumors.

The invention belongs to the technical field of organic radiation luminescence and radiation imaging, and discloses an aggregation-induced delayed fluorescence (AIDF) type organic scintillator material and a preparation method thereof, and a preparation method and application of a flexible organic scintillation film. The molecular structure of the material comprises carbonyl, methylene, sulfuryl and other connecting units, phthalonitrile is used as an acceptor unit, carbazole is used as a donor unit, an aggregation-induced excitation state is formed through space charge transfer among molecules, efficient AIDF luminescence and large Stokes shift characteristics are realized, the self-absorption phenomenon is effectively avoided, and the luminescent efficiency is improved. The X-ray fluorescence probe is suitable for a luminescence process under an X-ray excitation condition, the sensitivity of X-ray detection is remarkably improved, and the lowest detection limit can reach 276nGy.s <-1 > and is far superior to the 5.5 mu Gy.s <-1 > standard required by medical diagnosis. Besides, the flexible scintillator film prepared based on the material system radiates and emits light within the waveband range of 450-750 nm and is perfectly matched with the response area of a silicon-based detector, X-ray imaging with the high signal-to-noise ratio is achieved, and the imaging resolution is as high as 20.01 lp.mm <-1 >.

Provided are a T-cell receptor (TCR) and the use thereof, wherein the TCR contains an α chain containing a variable region and / or a β chain containing a variable region. The TCR is capable of specifically recognizing an A1101-restricted KRASG12V mutation and an A1101-restricted KRASG12D mutation. A T cell transducing the TCR (TCR-T) can bind to an antigen short peptide-HLA-A1101 complex, and can be used for treating malignant tumors carrying the KRASG12V mutation and KRASG12D mutation.

The invention relates to application of receptor-like kinase MdRLK2 in comprehensive resistance breeding of apples. After the receptor-like kinase MdRLK2 is instantaneously overexpressed in the apple tissue culture seedling Gal-3 and the apple Gala branch, it is found that the improvement of the expression quantity of the receptor-like kinase MdRLK2 effectively enhances the capability of resisting alternaria leaf spot, anthrax leaf blight, brown spot, rot disease and ring spot of apples; therefore, a molecular means for improving the comprehensive disease resistance of the apples is developed by overexpressing the apple receptor-like kinase MdRLK2, and meanwhile, a theoretical basis is provided for molecular breeding of the apples.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

The invention belongs to the technical field of gene engineering, and particularly relates to a biotin ligase mutant as well as a coding gene, an expression vector, a recombinant cell and application thereof. The amino acid sequence of the biotin ligase mutant is as shown in SEQ ID NO. 2. The biotin ligase (Bar A) mutant provided by the invention can be efficiently expressed in eukaryotes, the expression level of the biotin ligase (Bar A) mutant is obviously improved in mammalian cells compared with a wild type, and the biotin ligase (Bar A) mutant has good catalytic activity after expression, can effectively catalyze biotinylation of protein containing a biotin receptor sequence, and has good application prospects. The method has a wide application prospect in the fields of biotinylated protein preparation, and protein labeling, positioning, immunodetection, affinity purification, function research and the like based on a biotin-avidin system (BAS).

The invention discloses keratinase Phyto-Keratinase and application of the keratinase Phyto-Keratinase. The keratinase Phyto-Keratinase comprises the following components: (1) protease which is coded by a nucleotide sequence as shown in SEQ ID NO.1; and / or (2) protease which is derived from bacillus subtilis, is coded by a nucleic acid sequence with more than 98% of identity with the SEQ ID NO.1 nucleotide sequence and has the characteristic of hydrolyzing keratin. According to the plant keratinase Phyto-Keratinase disclosed by the invention, the Phyto-Keratinase (plant keratinase) produced by utilizing microbial fermentation is a serine proteolytic enzyme, is also a biocompatible cutinase, and is obtained by fermenting saccharomyces cerevisiae. Phyto-Keratinase provides a nitrogen source for the growth of plants (beans), and contains various amino acids (functional peptides) and special proteolytic enzymes derived from the plants at the same time. The Phyto-keratinase can provide the effects of resisting inflammation, removing cutin and providing nutrition for skin regeneration at the same time, can relieve various inflammations by inhibiting PAR-2 receptors, and has potential value in the fields of cosmetics, beauty medicine and environment.

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof for treating thyroid eye disease (TED) are provided herein. Anti-IGF-1R antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.

The invention discloses an MUC1-CAR-T cell for co-expressing a BTLA / IL-18R chimeric receptor as well as a preparation method and application of the MUC1-CAR-T cell, and belongs to the technical field of biological medicines. The MUC1-CAR-T cell comprises a BTLA / IL-18R chimeric receptor and an MUC1-CAR structure, wherein the BTLA / IL-18R chimeric receptor is a BTLA MUC1 is used as a targeting molecule for CAR-T cell therapy, an extracellular domain of BTLA is connected with a transmembrane domain and an intracellular domain of an IL-18 receptor, and the co-expression BTLA / IL-18R chimeric receptor is designed. Experimental verification shows that the BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cells, can better inhibit the growth of tumors, and provides a novel immunotherapy strategy for the treatment of pancreatic cancer.

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (VH) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.

The invention discloses an arabidopsis thaliana RK3 gene and application of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene in improvement of plant disease resistance, and belongs to the technical field of plant genetic engineering. According to the application of the arabidopsis thaliana RK3 gene to improvement of plant disease resistance, the nucleotide sequence of the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.1, the amino acid sequence of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.2, and further plants are selected from arabidopsis thaliana, oilseed rape, rice, tomatoes, potatoes, peanuts, soybeans, cotton, tobacco, cucumbers, watermelons and the like. The expression of the plant disease resistance comprises infection resistance to wild-type pseudomonas syringae, effector engineering strains thereof and botrytis cinerea. It is clear that the arabidopsis thaliana RK3 gene and the encoded protein thereof can remarkably enhance the infection resistance of plants to various pathogenic bacteria for the first time, disease prevention and control are achieved by activating the autoimmune system of the plants, and an effective path is provided for reducing chemical pesticide application and promoting agricultural green development.

The invention belongs to the technical field of bioengineering, and discloses a sunflower seed peptide for regulating metabolism of brain cells, the sunflower seed peptide has a biological sequence of Arg His Ala Lys Thr Pro Ser Asn Lys, and a preparation method of the sunflower seed peptide for regulating metabolism of brain cells comprises the following specific steps: S1, raw material pretreatment; s2, peeling and crushing; s3, protein extraction; s4, performing enzymolysis treatment; s5, performing enzyme deactivation treatment; s6, filtering and purifying; s7, concentrating and drying; and S8, quality detection and packaging. The sunflower seed protein is directionally decomposed into the active peptide fragment by precisely regulating and controlling compound protease and enzymolysis conditions, the active peptide fragment can be compatible with a brain cell specific receptor and penetrate through a blood brain barrier, and cell experiments and animal models prove that the peptide fragment can activate a mitochondrial respiratory chain complex, so that the mitochondrial membrane potential is increased by more than 30%, and the mitochondrial membrane potential is increased by more than 30%. Meanwhile, the activity of neurotransmitter synthetase can be enhanced, the brain health is protected, and tests further prove that the sunflower seed peptide also has the function of regulating the metabolism of brain cells.

The invention relates to the field of bioinformatics and computational biology, in particular to a method for realizing accurate alignment of biological slices by utilizing a spatial graph network and a cell communication network based on the biological slices of a graph attention network. The method mainly comprises the following steps: (1) acquiring a high-resolution biological slice image and spatial transcriptome data of a target tissue or brain region (such as DLPFC), and carrying out standardization processing on the high-resolution biological slice image and spatial transcriptome data; (2) constructing a space diagram network based on cell space distribution, and constructing a cell communication network by using a ligand-receptor database; (3) carrying out feature fusion and deep learning training by adopting GAT, extracting high-dimensional features, and designing a comprehensive loss function fusing a mean square error and triple loss based on MNN at the same time; and (4) globally optimizing rotation, translation and X-axis overturning parameters through a differential evolution algorithm, realizing precise alignment of the slices, and evaluating an alignment effect by a consistency index.

Provided are a recombinant human interleukin-11 mutant, and a conjugate of the mutant conjugated to a chemical molecule and a use thereof. The recombinant human interleukin-11 mutant achieves soluble expression in an Escherichia coli expression system by means of an SUMO sequence tandem fusion method. The conjugate is obtained by the site-specific conjugation of the mutant to the chemical molecule at a mutant amino acid residue in position W147 by means of a covalent bond. The chemical molecule is at least one of polyethylene glycol, an alkanoic acid aliphatic chain, and a hydrophilic high-molecular polymer containing an alkanoic acid aliphatic chain. The conjugate retains the binding capacity to human interleukin-11 receptor A while demonstrating significantly reduced binding capacity to human IL-6 signal transducer receptor. The conjugate shows the ability to block the signaling between human IL-11 and IL-11 RA and between human IL-11 and GP130 either in vivo or in vitro and can be used for the treatment of associated diseases with tissue fibrosis as a clinical manifestation caused by elevated primary or secondary IL-11.

The invention relates to the technical field of biology, in particular to a rice salt stress regulation gene OsMTA1 and application thereof.The rice salt stress regulation gene OsMTA1 is obtained by conducting CRISPR gene editing on the OsMTA1 gene, and compared with receptor rice Zhonghua 11 (ZH11), after two independent strains with mutants knocked out of the transgenic rice OsMTA1 gene are subjected to 180mM NaCl simulated salt stress treatment, the rice salt stress regulation gene OsMTA1 is obtained. After recovery treatment, phenotype observation and survival rate statistics are carried out, it is confirmed that the osmta1 mutant has a salt-sensitive phenotype compared with wild type ZH11, and it is indicated that the OsMTA1 gene plays an important role in the process of responding to rice salt stress.

The invention relates to recombinant pichia pastoris for high expression of porcine pancreatic phospholipase A2 and application of the recombinant pichia pastoris, and belongs to the technical field of genetic engineering. According to the method disclosed by the invention, a vacuole sorting receptor Vps10 is knocked out by utilizing a CRISPR-Cas9 system, a CPY sorting way between a trans-golgi apparatus and a vacuole is interrupted, and ppPLA2 degradation is reduced; then, in order to relieve unfolded protein response in the endoplasmic reticulum, molecular chaperones are introduced into the genome, and synthesis of ppPLA2 is enhanced; the expression intensity of the ppPLA2 is improved by increasing the gene copy number of the ppPLA2; and finally, high-density fermentation is performed in a 3-L bioreactor, so that high-efficiency expression of the ppPLA2 in the pichia pastoris is realized.

The embodiment of the invention discloses a coprophilous fungus transplantation donor and acceptor dynamic matching method, device and equipment and a medium, and the method comprises the steps: responding to a donor and acceptor matching request, and obtaining the monitoring data of a to-be-matched acceptor after coprophilous fungus transplantation at the current preset sampling time; wherein the monitoring data after coprophilous fungus transplantation is determined on the basis of the coprophilous fungus transplantation operation of a to-be-matched receptor completed by the coprophilous fungus flora of any target donor, and the target donor is determined by performing adaptability matching on the gene feature information, the immune feature information and the clinical feature information of the to-be-matched receptor and a plurality of to-be-selected donors; and inputting monitoring data after coprophilous fungi transplantation into the transplantation strategy control model, outputting at least one of a donor switching strategy and a dose adjustment strategy for adjusting a to-be-matched receptor in a next time period, realizing comprehensive compatibility evaluation through multi-modal data integration, continuously optimizing a treatment scheme by means of a dynamic feedback mechanism, and improving the compatibility of the to-be-matched receptor. And the accuracy and adaptability of coprophilous fungus transplantation treatment are remarkably improved.